364 results on '"Dytfeld, Dominik"'
Search Results
2. Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma
3. Mass spectrometry–based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma
4. G6PD deficiency—does it alter the course of COVID-19 infections?
5. Measurable residual disease in peripheral blood in myeloma: dream or reality
6. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma
7. Health-related quality of life in patients with multiple myeloma treated in the phase 3 ATLAS trial of post-transplant maintenance with carfilzomib, lenalidomide, dexamethasone or lenalidomide alone
8. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial
9. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
10. Therapy-related myeloid malignancies in patients with multiple myeloma.
11. T-cell exhaustion in multiple myeloma.
12. Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma
13. Efficacy of daratumumab monotherapy in real-world heavily pretreated patients with relapsed or refractory multiple myeloma
14. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders
15. Maintenance therapy after Autologous Stem Cell Transplantation in Multiple Myeloma -- currents and perspectives.
16. Nivolumab and daratumumab combination regimens for the treatment of relapsed and refractory multiple myeloma: results of a randomized phase I/II clinical trial
17. Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis of the randomized phase 3 ATLAS trial
18. POSTER: MM-464 LocoMMotion: A Prospective, Observational, Multinational Study of Real-Life Current Standards of Care in Patients With Relapsed/Refractory Multiple Myeloma – Final Analysis at 2-Year Follow-Up
19. P-324 LocoMMotion: a prospective, observational, multinational study of real-life current standards of care in patients with relapsed/refractory multiple myeloma–final analysis at 2-year follow-up
20. OA-45 Pharmacokinetic and correlative analysis of ciltacabtagene autoleucel in patients with lenalidomide-refractory multiple myeloma in the CARTITUDE-4 trial
21. MM-464 LocoMMotion: A Prospective, Observational, Multinational Study of Real-Life Current Standards of Care in Patients With Relapsed/Refractory Multiple Myeloma – Final Analysis at 2-Year Follow-up
22. P1103: OBINUTUZUMAB INDUCTION AND MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY WALDENSTRÖM MACROGLOBULINAEMIA
23. P923: COMPARATIVE EFFECTIVENESS OF TALQUETAMAB VS REAL-WORLD PHYSICIAN’S CHOICE OF TREATMENT IN LOCOMMOTION AND MOMMENT FOR PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA
24. P904: LOCOMMOTION: A PROSPECTIVE, OBSERVATIONAL, MULTINATIONAL STUDY OF REAL-LIFE CURRENT STANDARDS OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA– FINAL ANALYSIS AT 2-YEAR FOLLOW-UP
25. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
26. Iksazomib u chorych z nawrotowym lub opornym na leczenie szpiczakiem plazmocytowym
27. Zalecenia Polskiej Grupy Szpiczakowej dotyczące rozpoznawania i leczenia szpiczaka plazmocytowego oraz innych dyskrazji plazmocytowych na rok 2017
28. Supplementary Figure 1. Effects of long term pan-caspase inhibition on autophagy in myeloma cells. from Synergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase-10–Dependent Apoptosis by Carfilzomib and Selinexor
29. Supplementary Figure 5. Anti-tumor response of all groups of mice treated with carfilzomib or selinexor alone and in combination. from Synergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase-10–Dependent Apoptosis by Carfilzomib and Selinexor
30. Supplementary Figure 4. Changes in body weight of mice receiving single agent or combination treatment with selinexor or carfilzomib. from Synergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase-10–Dependent Apoptosis by Carfilzomib and Selinexor
31. Supplementary Materials and Methods from Synergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase-10–Dependent Apoptosis by Carfilzomib and Selinexor
32. Supplementary Figure 3. Western blot analysis of myeloma PC derived from three relapsed/refractory patients treated with selinexor and carfilzomib, alone and in combination. from Synergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase-10–Dependent Apoptosis by Carfilzomib and Selinexor
33. Supplementary Figure 2. Representative images used in aggresome analysis. from Synergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase-10–Dependent Apoptosis by Carfilzomib and Selinexor
34. Supplementary Figure 7. Immunofluorescent localization of Fas and p62. from Synergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase-10–Dependent Apoptosis by Carfilzomib and Selinexor
35. Supplementary Figure 6. Effects of caspase inhibitors alone on myeloma cell viability. from Synergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase-10–Dependent Apoptosis by Carfilzomib and Selinexor
36. SARS-CoV-2 infection in patients with multiple myeloma: survey in 23 centers across Europe and USA
37. Zalecenia Polskiej Grupy Szpiczakowej dotyczące rozpoznawania i leczenia szpiczaka plazmocytowego oraz innych dyskrazji plazmocytowych na rok 2016
38. Second allogeneic hematopoietic stem cell transplantation for relapsed acute myeloid leukaemia: a retrospective single-centre analysis of the outcome
39. A Stepwise Screening Protocol for Multiple Myeloma
40. Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial
41. Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial
42. Zalecenia Polskiej Grupy Szpiczakowej dotyczące rozpoznawania i leczenia szpiczaka plazmocytowego oraz innych dyskrazji plazmocytowych na rok 2015
43. Optimization of treatment of patients with plasma cell myeloma with high cytogenetic risk in Poland
44. Inhibitory effects of bortezomib on platelet aggregation in patients with multiple myeloma
45. P-264: Updated results from LocoMMotion: A prospective, noninterventional, multinational study of real-life current standards-of-care in heavily pretreated patients with relapsed/refractory multiple myeloma
46. P-243: Subgroup analyses from the LocoMMotion study of real-life current standard of care (SOC) in patients with relapsed/refractory multiple myeloma (RRMM)
47. OAB-010: Atlas: a phase 3 randomized trial of carfilzomib, lenalidomide, and dexamethasone versus lenalidomide alone after stem-cell transplant for multiple myeloma
48. Post-transplant carfilzomib, lenalidomide, and dexamethasone outperforms post-transplant lenalidomide in multiple myeloma
49. Translational research w szpiczaku plazmocytowym polską szansą na przyspieszenie?
50. Zalecenia Polskiej Grupy Szpiczakowej dotyczące rozpoznawania i leczenia szpiczaka plazmocytowego oraz innych dyskrazji plazmocytowych na rok 2013
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.